HPLC-MS/MS method for the determination of cytarabine in human plasma

Bioanalysis

Volumn 3, Issue 14, 2011, Pages 1603-1611

  Hilhorst, Martijn J ^a   Hendriks, Gert ^a   Van Hout, Mischa W J ^a   Sillén, Henrik ^b   Van De Merbel, Nico C ^a,c  

^a PRA Health Sciences   (Netherlands)

^b ASTRAZENECA R AND D   (Sweden)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; CYTARABINE DERIVATIVE; CYTIDINE; TETRAHYDROURIDINE;

ACCURACY; ANALYTIC METHOD; ARTICLE; CATION EXCHANGE; CENTRIFUGATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SENSITIVITY; DRUG STABILITY; DRUG STRUCTURE; ENVIRONMENTAL TEMPERATURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROPHILICITY; LIMIT OF QUANTITATION; PRECIPITATION; PROCESS OPTIMIZATION; QUANTITATIVE ANALYSIS; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; TEMPERATURE DEPENDENCE; VALIDATION PROCESS;

ANTIMETABOLITES, ANTINEOPLASTIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; CYTARABINE; DRUG STABILITY; HUMANS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 79960526357     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.11.140     Document Type: Article

References (12)

1. Rustum M, Raymakers RA. 1-b-arabinofuranosylcytosine in therapy of leukemia: preclinical and clinical overview. Pharmacol. Ther. 56(3), 307-321 (1993).
2. Sun Y, Sun J, Wen B et al. High performance liquid chromatography-tandem mass spectrometry method for the simultaneous determination of cytarabine and its valyl prodrug valcytarabine in rat plasma. J. Chromatogr. B 870, 121-125 (2008).
3. Scott-Moncrieff JCR, Chan TCK, Samuels ML et al. Plasma and cerebrospinal fluid pharmacokinetics of cytosine arabinoside in dogs. Cancer Chemother. Pharmacol. 29, 13-18 (1991).
4. Gómez C, Blanco MD, Bernardo MV, Olmo R, Muniz E, Teijon JM. Cytarabine release from comatrices of albumin microspheres in a poly (lactide-co-glycolide) film: in vitro and in vivo studies. Eur. J. Pharm. Biopharm. 57, 225-233 (2004). (Pubitemid 38283698)
5. Burk M, Volmer M, Fartash K, Schneider W. Ion-pair liquid chromatography of cytarabine and uracil-arabinoside in human plasma. Arzniem. Forsch. Drug. Res. 45, 616-619 (1995).
6. Mistiran AF, Dzarr AA, Gan SH. HPLC method development and validation for simultaneous detection of arabinoside-C and doxorubicin. Toxicol. Mech. Methods. 20, 472-481 (2010).
7. Hsieh Y, Li F, Duncan CJG. Supercritical fluid chromatography and high performance liquid chromatography-tandem mass spectrometric methods for the determination of cytarabine in mouse plasma. Anal. Chem. 79, 3856-3861 (2007). (Pubitemid 46799083)
8. Hsieh Y, Duncan CJG. An ion-pairing liquid chromatography-tandem mass spectrometric method for the determination of cytarabine in mouse plasma. Rapid Commun. Mass Spectrom. 21, 573-578 (2007). (Pubitemid 46294307)
9. Hsieh Y, Duncan CJG, Liu M. A mixed-mode liquid chromatography-tandem mass spectrometric method for the determination of cytarabine in mouse plasma. J. Chromatogr. B 854, 8-12 (2007). (Pubitemid 46962355)
10. Hsieh Y, Duncan CJG, Brisson JM. Porous graphitic carbon chromatography-tandem mass spectrometric determination of cytarabine in mouse plasma. Rapid Commun. Mass Spectrom. 21, 629-634 (2007). (Pubitemid 46340305)
11. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine. Guidance for Industry - Bioanalytical Method Validation (2001).
12. Wen B, Sun Y, Xu Y. Pharmacokinetic characteristics of the cytarabine prodrug, ilecyterabine, after intravenous and oral administration to rats. Asian J. Pharm. Sci. 3, 200-210 (2008